The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer modelsClara Lemos, Bernard Haendler|Cellular Oncology|2021Cited by 42
Dual targeting of the androgen receptor and <scp>PI3K</scp> / <scp>AKT</scp> / <scp>mTOR</scp> pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosisTatsuo Sugawara, Bernard Haendler|Molecular Oncology|2024Cited by 20
Comparative Proteomic and Transcriptomic Analysis of the Impact of Androgen Stimulation and Darolutamide InhibitionEkaterina Nevedomskaya, Bernard Haendler|Cancers|2022Cited by 3
The Potent and Selective AMPK Inhibitor BAY-3827 Shows Strong Efficacy in Androgen-Dependent Prostate Cancer ModelsClara Lemos, Bernard Haendler|Research Square|2020Cited by 1